DEA Eyes Bulk Production of Psilocybin and Fentanyl—Wait, What?
Published Date: 3/26/2026
Notice
Summary
SpecGx LLC wants to become a big-time maker of some powerful and tightly controlled drugs, including things like psilocybin and fentanyl. People and companies already registered can share their thoughts or ask for a hearing by May 26, 2026. This move could shake up how these substances are made and handled, so keep an eye on the deadlines if you’re involved!
Analyzed Economic Effects
4 provisions identified: 0 benefits, 0 costs, 4 mixed.
SpecGx Applied To Bulk-Produce Many Drugs
SpecGx LLC applied on February 4, 2026 to be registered as a bulk manufacturer for many Schedule I and II controlled substances, including psilocybin (code 7437), fentanyl and related compounds (codes 9801, 9821, 9822, 9850), tetrahydrocannabinols (code 7370), and gamma hydroxybutyric acid (code 2010). The notice lists the full set of drug codes the company seeks to manufacture in bulk.
Deadline to Comment or Request Hearing
Registered bulk manufacturers of the affected drug classes and applicants may submit electronic comments or objections, or file a written request for a hearing, on or before May 26, 2026. Comments must be submitted via https://www.regulations.gov and commenters will receive a Comment Tracking Number when submitted.
Planned Sale And Internal Use Of Manufactured Drugs
SpecGx plans to bulk manufacture the listed controlled substances for sale to its customers and for internal use to produce non-controlled substances, according to the application text. The registration, if granted, would be limited to the activities listed for those drug codes.
THC Manufacture Limited To Synthetic Form
For drug code 7370 (Tetrahydrocannabinols), SpecGx states it plans to bulk manufacture this drug code as synthetic. The application notes that no other activities for these drug codes are authorized by this registration.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-10090 — Exempt Chemical Preparations Under the Controlled Substances Act
The Drug Enforcement Administration (DEA) reviewed and decided on applications for special chemical mixtures that don’t fall under strict drug rules, covering requests from July 2025 to March 2026. Some mixtures got approved, others denied, and a few listings were fixed from earlier notices. If you’re involved with these chemicals, you’ve got until July 20, 2026, to share your thoughts—no fees or big costs involved, just your voice!
2026-09566 — Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I
Starting May 13, 2026, the DEA officially puts CUMYL-PEGACLONE—a chemical that can be risky—into Schedule I, the strictest drug category. This means anyone making, selling, or using it now faces tough rules and penalties. This move helps the U.S. follow international drug laws and keeps communities safer without any new fees or costs.
2026-08595 — Specific Listing for Hexahydrocannabinol, A Currently Controlled Schedule I Substance
The DEA is giving hexahydrocannabinol (HHC) its own official spot on the list of Schedule I drugs, making it clear that HHC is controlled separately from other similar substances. This change starts May 4, 2026, and affects anyone making, selling, or using HHC, which stays illegal under federal law. No new fees or costs are introduced, but the update helps law enforcement and businesses know exactly where HHC stands.
2026-08587 — Importer of Controlled Substances Application: ANI Pharmaceuticals Inc.
ANI Pharmaceuticals wants to import certain controlled drugs like Levorphanol and Tapentadol. People who make or use these drugs can share their thoughts or ask for a hearing by June 3, 2026. This move could affect drug availability and regulation, so keep an eye on the deadline to have your say!
2026-08588 — Bulk Manufacturer of Controlled Substances Application: Patheon API Inc.
Patheon API Inc. wants to make large amounts of special research drugs like dimethyltryptamine and psilocybin. This affects researchers and companies involved in clinical trials, with a chance to comment or ask for a hearing by July 6, 2026. No money changes are mentioned, but this move could speed up important medical studies.
Previous / Next Documents
Previous: 2026-05911 — Notice Pursuant to the National Cooperative Research and Production Act of 1993-R Consortium, Inc.
R Consortium, a group of companies working together on research, announced that Oracle, Google, and Genentech have left the team. This update keeps the group’s special legal protections in place and lets others still join. No money changes or new projects were mentioned, and the group will keep sharing updates as members come and go.
Next: 2026-05913 — Elite Laboratories, Inc., et al.; Withdrawal of Approval of 72 Abbreviated New Drug Applications; Correction
The FDA fixed a mistake about pulling approvals for 72 generic drug applications. One drug, a valproic acid capsule from Upsher-Smith Laboratories, won’t lose its approval because the company asked to keep it. This means the drug stays available, and the change took effect before October 23, 2025.